It is well known that the EGFR-sensitive mutation enhances the phosphorylation of MAPK and Akt in NSCLC, and our previous studies and others had documented that GPER1 can stimulate the phosphorylation of MAPK and Akt through activation of EGFR in breast cancer. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.